CRISM Therapeutics Interim Earnings Report

CRISM Therapeutics EPS Results

• Actual EPS: -GBX 2.60
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

CRISM Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

CRISM Therapeutics Announcement Details

• Quarter: Interim
• Date: 9/21/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

CRISM Therapeutics (LON:CRTX) is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1 2026. For more information please visit: https://www.crismtherapeutics.com